Category: Our News

The Canadian Cancer Society, the Quebec Breast Cancer Foundation and CQDM join forces to fight breast cancer

Montreal, June 18, 2020  – The Canadian Cancer Society (CCS) and the Quebec Breast Cancer Foundation (QBCF), two leading organizations in funding breast cancer research, together with the biopharmaceutical research consortium CQDM, are proud to support the research conducted by Professor Yves St-Pierre at INRS-Institut Armand-Frappier. Valued at $1.15M, the project will support the development…

CQDM grants $1.15 M in funding to Professor Yves St-Pierre’s team to develop a revolutionary immunotherapy against breast cancer

Pr. Yves St-Pierre – INRS Montreal, June 18, 2020 – CQDM partners with the Canadian Cancer Society (CCS), the Quebec Breast Cancer Foundation (QBCF), the Armand-Frappier Foundation, the Canadian Glycomics Network (GlycoNet), Zymeworks and Pfizer as part of a $1.15M funding agreement. These funds will enable Professor Yves St-Pierre and his colleagues, Professors David Chatenet…

New call for proposals under the Fonds d’accélération des collaborations en santé

June 16th 2020 – The Government of Quebec is launching the second call for proposals under the Fonds d’accélération des collaborations en santé (FACS). Consortia of partners from the public, private and non-profit sectors are invited to submit structuring projects that meet the current and future practical needs of companies in the life sciences sector.…

Theratechnologies Unveils New Positive Data For Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers

May 15th – 2020 – CQDM congratulates Theratechnologies and UQAM’s Professor Borhane Annabi for the positive results presented at the Virtual Annual Meeting II of the American Association for Cancer Research (AACR), particularly those obtained with its docetaxel-peptide conjugate TH-1902 for the treatment of triple-negative breast cancer. These are very encouraging results! To read Theratechnologies press…

Collaborative project of more than $1.2 million using artificial intelligence to optimize the production of vaccines, announced by CQDM and Medicago R&D

Quebec City, Quebec, May 5th, 2020 – The biopharmaceutical research consortium CQDM and Medicago R&D  are proud to announce today the funding of a research project that will allow the Quebec City-based company to increase the competitiveness of its vaccine production platform and confirm its position as leader in the biopharmaceutical industry in Canada. Through CQDM,…

Pre-launch of a new call for proposals in June 2020: discover the latest updates!

Fonds d’accélération des collaborations en santé (Health Collaboration Acceleration Fund) May 27th 2020 – To stimulate economic recovery in the life sciences sector, the Government of Quebec is making changes to the Fonds d’accélération des collaborations en santé (FACS) and inviting actors of the ecosystem to collaborate by launching ambitious projects that meet the practical needs…

CQDM welcomes Zymeworks as a new member of CQDM’s biopharmaceutical consortium

Montreal, February 27, 2020 – CQDM is pleased to welcome Zymeworks Inc. as a new member of its biopharmaceutical research consortium established to identify and invest in highly innovative biopharmaceutical research projects in Quebec and Canada with the ultimate goal of enabling the development of better treatments for patients. As a CQDM member, Zymeworks will…

2nd Annual Gordon Shore Prize – Call for Proposal to Private Companies

Private companies based in Quebec with biopharmaceutical-related activities are invited to propose postdoctoral internship positions for new doctoral graduates, future awardees of the Gordon Shore Prize. Award sponsors, CQDM, Diazon Pharmaceuticals and Mitacs will finance 50% of these postdoctoral internships. The company must agree to pay the other half of the new graduate’s salary. The application…